Q-omics provides the consensus-scored LPAR5 profile across patient tissues and cancer cell-line models. LPAR5 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, LPAR5 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LPAR5 RNA expression shows 18,086 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, KIRC, and UVM as cancer lineages where LPAR5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LPAR5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LPAR5 survival associations across molecular data types. LPAR5 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LPAR5 RNA expression–survival associations across cancer types. High LPAR5 expression shows unfavorable associations in LGG, but favorable associations in THCA, SKCM, UCEC, ACC and SCLC. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for LPAR5 RNA expression.
This table summarizes LPAR5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LPAR5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LPAR5 shows higher tumor expression in KIRC, THCA, KIRP, LUAD, LUSC and HNSC. The KIRC box plot shows higher LPAR5 RNA expression in tumor versus normal tissue (log2 FC = +1.931, t-test p < 0.001).
This table shows molecular features associated with LPAR5 in patient tissues and cancer cell lines. In patient samples, LPAR5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LPAR5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
